Article
PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS
Neuro-oncology
(2018)
Disciplines
Publication Date
November 5, 2018
DOI
10.1093/NEUONC/NOY148.685
Citation Information
Yao Yu, Stephanie Hilz, Matthew Grimmer, David Solomon, et al.. "PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS" Neuro-oncology Vol. 20 (2018) Available at: http://works.bepress.com/michael-mcdermott/136/